TrialScientific reports2023

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

R F Schlenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.